These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 12744870

  • 1. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18-36 months of age.
    Qadri F, Ahmed T, Ahmed F, Bradley Sack R, Sack DA, Svennerholm AM.
    Vaccine; 2003 Jun 02; 21(19-20):2394-403. PubMed ID: 12744870
    [Abstract] [Full Text] [Related]

  • 2. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi adults and children.
    Qadri F, Wennerâs C, Ahmed F, Asaduzzaman M, Saha D, Albert MJ, Sack RB, Svennerholm A.
    Vaccine; 2000 Jun 01; 18(24):2704-12. PubMed ID: 10781858
    [Abstract] [Full Text] [Related]

  • 3. Induction of systemic antifimbria and antitoxin antibody responses in Egyptian children and adults by an oral, killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine.
    Hall ER, Wierzba TF, Ahrén C, Rao MR, Bassily S, Francis W, Girgis FY, Safwat M, Lee YJ, Svennerholm AM, Clemens JD, Savarino SJ.
    Infect Immun; 2001 May 01; 69(5):2853-7. PubMed ID: 11292698
    [Abstract] [Full Text] [Related]

  • 4. Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: dosing studies in different age groups.
    Qadri F, Ahmed T, Ahmed F, Begum YA, Sack DA, Svennerholm AM, PTE Study Group.
    Vaccine; 2006 Mar 06; 24(10):1726-33. PubMed ID: 16257098
    [Abstract] [Full Text] [Related]

  • 5. Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial.
    Qadri F, Akhtar M, Bhuiyan TR, Chowdhury MI, Ahmed T, Rafique TA, Khan A, Rahman SIA, Khanam F, Lundgren A, Wiklund G, Kaim J, Löfstrand M, Carlin N, Bourgeois AL, Maier N, Fix A, Wierzba T, Walker RI, Svennerholm AM.
    Lancet Infect Dis; 2020 Feb 06; 20(2):208-219. PubMed ID: 31757774
    [Abstract] [Full Text] [Related]

  • 6. Safety and immunogenicity of two different lots of the oral, killed enterotoxigenic escherichia coli-cholera toxin B subunit vaccine in Israeli young adults.
    Cohen D, Orr N, Haim M, Ashkenazi S, Robin G, Green MS, Ephros M, Sela T, Slepon R, Ashkenazi I, Taylor DN, Svennerholm AM, Eldad A, Shemer J.
    Infect Immun; 2000 Aug 06; 68(8):4492-7. PubMed ID: 10899847
    [Abstract] [Full Text] [Related]

  • 7. Dose-dependent circulating immunoglobulin A antibody-secreting cell and serum antibody responses in Swedish volunteers to an oral inactivated enterotoxigenic Escherichia coli vaccine.
    Jertborn M, Ahrén C, Svennerholm AM.
    Clin Diagn Lab Immunol; 2001 Mar 06; 8(2):424-8. PubMed ID: 11238232
    [Abstract] [Full Text] [Related]

  • 8. Safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli vaccine.
    Jertborn M, Ahrén C, Holmgren J, Svennerholm AM.
    Vaccine; 1998 Mar 06; 16(2-3):255-60. PubMed ID: 9607039
    [Abstract] [Full Text] [Related]

  • 9. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A, Giraldo A, Castañeda E, Martínez M, de la Hoz F, Rivas F, Depetris A, Svennerholm AM, Sack DA.
    Bull Pan Am Health Organ; 1995 Dec 06; 29(4):312-21. PubMed ID: 8605522
    [Abstract] [Full Text] [Related]

  • 10. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
    Holmgren J, Bourgeois L, Carlin N, Clements J, Gustafsson B, Lundgren A, Nygren E, Tobias J, Walker R, Svennerholm AM.
    Vaccine; 2013 May 07; 31(20):2457-64. PubMed ID: 23541621
    [Abstract] [Full Text] [Related]

  • 11. Antibody-secreting cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine.
    Wennerås C, Svennerholm AM, Ahrén C, Czerkinsky C.
    Infect Immun; 1992 Jul 07; 60(7):2605-11. PubMed ID: 1612730
    [Abstract] [Full Text] [Related]

  • 12. Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: results of the initial evaluation in children. PRIDE Study Group.
    Savarino SJ, Hall ER, Bassily S, Brown FM, Youssef F, Wierzba TF, Peruski L, El-Masry NA, Safwat M, Rao M, El Mohamady H, Abu-Elyazeed R, Naficy A, Svennerholm AM, Jertborn M, Lee YJ, Clemens JD.
    J Infect Dis; 1999 Jan 07; 179(1):107-14. PubMed ID: 9841829
    [Abstract] [Full Text] [Related]

  • 13. Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein.
    Lundgren A, Leach S, Tobias J, Carlin N, Gustafsson B, Jertborn M, Bourgeois L, Walker R, Holmgren J, Svennerholm AM.
    Vaccine; 2013 Feb 06; 31(8):1163-70. PubMed ID: 23306362
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Double-blind, randomized, placebo controlled pilot study evaluating efficacy and reactogenicity of an oral ETEC B-subunit-inactivated whole cell vaccine against travelers' diarrhea (preliminary report).
    Wiedermann G, Kollaritsch H, Kundi M, Svennerholm AM, Bjare U.
    J Travel Med; 2000 Jan 06; 7(1):27-9. PubMed ID: 10689236
    [Abstract] [Full Text] [Related]

  • 18. Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study.
    Lundgren A, Bourgeois L, Carlin N, Clements J, Gustafsson B, Hartford M, Holmgren J, Petzold M, Walker R, Svennerholm AM.
    Vaccine; 2014 Dec 12; 32(52):7077-84. PubMed ID: 25444830
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.